Drug intelligence / Profile preview

CYR61 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

CYR61 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the *CYR61* (Cysteine-rich angiogenic inducer 61) gene, also known as *CCN1*. CYR61 is a secreted, heparin-binding protein and a member of the CCN family that plays a pivotal role in cell adhesion, migration, proliferation, and angiogenesis. In various cancers, including prostate cancer, CYR61 expression is often upregulated—frequently induced by growth factors such as IGF1—and promotes tumor progression and metastasis by activating the PI3K/AKT signaling pathway. By utilizing the RNA interference (RNAi) pathway, CYR61 siRNA specifically targets and mediates the degradation of CYR61 mRNA, leading to a significant reduction in protein levels. This silencing results in the inhibition of tumor cell growth, viability, and colony formation, making it a potential therapeutic strategy for limiting tumor growth and metastatic spread.

Other names
CCN1 siRNACCN-1 siRNACCN 1 siRNAsiRNA targeting CYR61Cysteine-rich angiogenic inducer 61 siRNA
02

Targets

CCN1 (Cellular communication network factor 5)

Beyond the preview

Go deeper on CYR61 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYR61 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call